Ultime notizie per T2 Biosystems (NASDAQ:TTOO) Azioni

T2 Biosystems

T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.

T2 Biosystems Inc

News

TTOO

T2 Biosystems And Prxcision Announce Co-Marketing Collaboration To Offer Rapid Direct-From-Blood Diagnostics And AI-Powered Decision Support Platform To Address Bloodstream Infections And Combat Antibiotic Resistance Crisis

Guidance

T2 Biosystems Sees Q4 Revenue $2.5M-$3.5M Vs $3.7M Est.

T2 Biosystems Sees Preliminary Q3 Revenue $2.0M VS $2.8M Est.

Biotech

General

T2 Biosystems Enters Multi-Year Exclusive U.S. Agreement With Cardinal Health To Sell FDA-Cleared Direct-From-Blood Diagnostics For Rapid Sepsis Detection, Including T2Dx Instrument, T2Bacteria Panel, And T2Candida Panel

T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted a recently published article in The Lancet, a world-leading medical journal. The article titled "Changing the Culture of Blood Culture" was authored by Sally&nbsp;Davies,&nbsp;Richard A&nbsp;Marfuggi,&nbsp;Rick A&nbsp;Bright,&nbsp;Steve&nbsp;Brozak, and&nbsp;Michael&nbsp;Osterholm on September 20, 2024.

T2 Biosystems Highlights New Article Published In The Lancet, Titled "Changing The Culture Of Blood Culture"

T2 Biosystems Successfully Defends Patent For Direct-From-Whole Blood Pathogen Detection Method In European Union, Maintaining Strong IP Position

T2 Biosystems Receives FDA Clearance To Market T2Candida Panel For Pediatric Patients, The Only Test Detecting Sepsis-Causing Candida Species Directly From Blood In 3-5 Hours Without Blood Culture; Panel Detects Five Candida Species Responsible For 95% Of U.S. Bloodstream Infections

<ul>
<li>Finalizing a 510(k) premarket notification application for the T2Resistance&#xAE; Panel planned to be filed with the U.S. Food and Drug Administration (FDA) during the fourth quarter of 2024.</li>
<li>The previously submitted 510(k) premarket notification to expand use of the T2Candida&#xAE; Panel to detect pediatric Candida infections is pending clearance with the FDA.</li>
<li>Advanced internal validation and plans to submit a 510(k) premarket notification to the FDA to expand the use of its FDA-cleared T2Bacteria&#xAE; Panel to detect pediatric bacterial infections.</li>
<li>The Company maintains its plan to launch the T2Lyme&#x2122; Panel as a Laboratory Developed Test (LDT); however, it now plans to build or buy its own laboratory rather than launch through a partnership.
<ul>
<li>Pursuing non-dilutive funding to complete the development, validation, and clinical studies for a diagnostic test to detect Candida auris, following the completion of feasibility and early development in collaboration with the U.S. Centers for Disease Control and Prevention (CDC).</li>
</ul>
</li>
</ul>

T2 Biosystems Provides Updates On New Product Development Pipeline Progress

<a href="https://www.tga.gov.au/resources/artg/459987" title="https://www.tga.gov.au/resources/artg/459987">https://www.tga.gov.au/resources/artg/459987</a>

Global

T2 Biosystems  Gets Australian Approval For Its T2Candida In Vitro Diagnostic For The Detection Of Sepsis-Causing Fungal Pathogens From Whole Blood

T2 Biosystems shares are trading higher after the company reported better-than-expected Q2 EPS results. Also, Canaccord Genuity maintained a Hold rating on the stock and raised its price target from $3 to $5.

Canaccord Genuity analyst Kyle Mikson maintains T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) with a Hold and raises the price target from $3 to $5.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Hold on T2 Biosystems, Raises Price Target to $5

T2 Biosystems Continues To Expect FY24 Total Sepsis Product Revenue Of $10M - $11M, Representing Growth Of 49% To 64% Y/Y

T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.97) by 31.96 percent. The company reported quarterly sales of $1.952 million which missed the analyst consensus estimate of $2.100 million by 7.05 percent. This is a 0.61 percent decrease over sales of $1.964 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

T2 Biosystems Q2 2024 GAAP EPS $(0.66) Beats $(0.97) Estimate, Sales $1.952M Miss $2.100M Estimate

Marks Continued International Expansion Following Recent Hong Kong And Macau Entry; Aims To Improve Sepsis Care Globally, Says CEO John Sperzel

T2 Biosystems Announces Exclusive Distribution Agreement In Malaysia And Indonesia; To Sell T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, And T2Resistance Panel

T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Hong Kong and Macau. Under the terms of the agreement, T2 Biosystems will sell the T2Dx&#xAE; Instrument, the T2Bacteria&#xAE; Panel, the T2Candida&#xAE; Panel, and the T2Resistance&#xAE; Panel through the newly appointed distributor.

T2 Biosystems Announces Commercial Expansion Through Hong Kong And Macau Distributor; T2 Biosystems Will Sell The T2dD Instrument, The T2Bacteria Panel, The T2Candida Panel, And The T2Resistance Panel Through The Newly Appointed Distributor

T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC ("Nasdaq") on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities ("MVLS") requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the "Rule") for continued listing on the Nasdaq Capital Market.

T2 Biosystems Regains Compliance With Nasdaq

<h3>Gainers</h3>
<ul>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) shares moved upwards by 205.8% to $1.56 during Thursday's regular session. The company's market cap stands at $2.7 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares moved upwards by 31.66% to $0.17. The company's market cap stands at $20.6 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock increased by 23.56% to $2.22. The market value of their outstanding shares is at $26.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) shares moved upwards by 23.35% to $0.1. The company's market cap stands at $3.4 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock moved upwards by 23.29% to $0.14. The market value of their outstanding shares is at $3.0 million. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock increased by 19.98% to $3.88. The market value of their outstanding shares is at $40.9 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 24.1% to $0.81 during Thursday's regular session. The market value of their outstanding shares is at $41.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock decreased by 22.17% to $1.51. The company's market cap stands at $1.3 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock decreased by 20.99% to $3.29. The market value of their outstanding shares is at $190.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares fell 17.31% to $8.6. The market value of their outstanding shares is at $87.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Biotricity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCY#NASDAQ">BTCY</a>) stock decreased by 11.41% to $1.01. The company's market cap stands at $9.5 million. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) stock decreased by 10.22% to $5.36. The market value of their outstanding shares is at $72.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATNF

BTCY

ELTX

EYEN

LSDI

NNVC

NRXP

OMER

ONCO

SCPX

SINT

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

T2 Biosystems shares are trading higher after the company announced an $8 million private placement.

<h3>Gainers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 136.2% to $0.13 during Wednesday's regular session. The company's market cap stands at $15.9 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares moved upwards by 45.55% to $6.06. The company's market cap stands at $81.9 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares rose 25.9% to $4.67. The company's market cap stands at $51.2 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares increased by 25.64% to $2.89. The company's market cap stands at $2.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares moved upwards by 22.8% to $12.87. The market value of their outstanding shares is at $234.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock increased by 20.57% to $1.0. The market value of their outstanding shares is at $50.7 million. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 67.0% to $0.76 during Wednesday's regular session. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 50.35% to $0.42. The company's market cap stands at $1.1 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock decreased by 37.84% to $3.27. The company's market cap stands at $2.1 million. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares declined by 33.12% to $0.88. The company's market cap stands at $33.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) shares fell 18.91% to $0.73. The market value of their outstanding shares is at $54.2 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares declined by 18.27% to $1.61. The market value of their outstanding shares is at $3.6 million. The company's, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

BBLG

BOLT

NTRB

OPRX

TCON

VRPX

YTEN

12 Health Care Stocks Moving In Wednesday's Intraday Session

Health Care

Financing

Offerings

T2 Biosystems Announced $8M Private Placement Including The Purchase And Sale Of An Aggregate Of 2.02M Shares, Series A Warrants To Purchase Up To 2.02M Shares, And Short-term Series B Warrants To Purchase Up To 2.02M At $3.95/Share

T2 Biosystems GAAP EPS of -$0.66 beats by $0.31, revenue of $1.95M misses by $0.15M

T2 Biosystems announces commercial expansion through Malaysia and Indonesia distributor

T2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
T2 Biosystems (NASDAQ:<a href="https://investorplace.com/stock-quotes/ttoo-stock-quote/">TTOO</a>) just reported results for the second quarter of 2024.<ul><li>T2 Biosystems reported earnings per share of -66 cents. This was above the analyst estimate for EPS of -97 cents.</li><li>The company reported revenue of $1.95 million.</li><li>This was 7.05% worse than the analyst estimate for revenue of $2.10 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/07/ttoo-stock-earnings-t2-biosystems-for-q2-of-2024/">TTOO Stock Earnings: T2 Biosystems Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TTOO Stock Earnings: T2 Biosystems Beats EPS, Misses Revenue for Q2 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning!



Moving stocks this morning are earnings reports, clinical trial results and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Imunon (NASDAQ:<a href="https://investorplace.com/stock-quotes/imnn-stock-quote/">IMNN</a>) stock is rocketing more than 133% alongside <a href="https://finance.yahoo.com/news/imunon-report-topline-results-phase-200500840.html">Phase 2 clinical trial results</a>.</li>



<li>Jet AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/jtai-stock-quote/">JTAI</a>) shares are soaring over 57% despite a lack of news this morning.</li>



<li>Enveric Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/envb-stock-quote/">ENVB</a>) stock is surging more than 32% with strong early morning trading.</li>



<li>Inspirato (NASDAQ:<a href="https://investorplace.com/stock-quotes/ispo-stock-quote/">ISPO</a>) shares are rising close to 26% without any clear news this morning.</li>



<li>Pharming (NASDAQ:<a href="https://investorplace.com/stock-quotes/phar-stock-quote/">PHAR</a>) stock is heading over 21% higher ahead of its <a href="https://www.nasdaq.com/press-release/pharming-group-report-second-quarter-and-first-half-2024-financial-results-august-1-0">upcoming earnings report</a>.</li>



<li>Sprouts Farmers Market (NASDAQ:<a href="https://investorplace.com/stock-quotes/sfm-stock-quote/">SFM</a>) shares are increasing more than 17% after <a href="https://investorplace.com/earning-results/2024/07/sfm-stock-earnings-sprouts-farmers-market-for-q2-of-2024/?utm_source=barchart&amp;utm_medium=allother">releasing its Q2 earnings</a>.</li>



<li>Harmonic (NASDAQ:<a href="https://investorplace.com/stock-quotes/hlit-stock-quote/">HLIT</a>) stock is climbing over 17% with its <a href="https://www.nasdaq.com/press-release/harmonic-announces-second-quarter-2024-results-2024-07-29">Q2 earnings report</a>.</li>



<li>Davis Commodities (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtck-stock-quote/">DTCK</a>) shares are gaining more than 15% on Tuesday morning.</li>



<li>T2 Biosystems (NASDAQ:<a href="https://investorplace.com/stock-quotes/ttoo-stock-quote/">TTOO</a>) stock is getting an over 14% boost with its <a href="https://www.nasdaq.com/press-release/t2-biosystems-announces-second-quarter-2024-financial-results-2024-07-29">latest earnings report</a>.</li>



<li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) shares are up more than 14% after announcing <a href="https://www.nasdaq.com/press-release/investor-one-one-meeting-requests-open-29th-annual-enercom-denver-energy-investment">investor meeting plans</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>QXO (NASDAQ:<a href="https://investorplace.com/stock-quotes/qxo-stock-quote/">QXO</a>) stock is crashing over 80% after <a href="https://finance.yahoo.com/news/high-flying-qxo-erases-36-221350996.html">announcing a private placement</a>.</li>



<li>BIMI (NASDAQ:<a href="https://investorplace.com/stock-quotes/bimi-stock-quote/">BIMI</a>) shares are plummeting more than 23% on Tuesday morning.</li>



<li>Ekso Bionics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ekso-stock-quote/">EKSO</a>) stock is diving over 22% alongside its <a href="https://finance.yahoo.com/news/ekso-bionics-ekso-reports-q2-214505963.html">Q2 earnings results</a>.</li>



<li>Symbotic (NASDAQ:<a href="https://investorplace.com/stock-quotes/sym-stock-quote/">SYM</a>) shares are tumbling more than 18% after <a href="https://finance.yahoo.com/news/symbotic-inc-sym-reports-q3-213008077.html">reporting a Q3 loss</a>.</li>



<li>Lattice Semiconductor (NASDAQ:<a href="https://investorplace.com/stock-quotes/lscc-stock-quote/">LSCC</a>) stock is taking an almost 18% beating with its <a href="https://seekingalpha.com/article/4707817-lattice-semiconductor-corporation-lscc-q2-2024-earnings-call-transcript?source=feed_all_articles">latest earnings report</a>.</li>



<li>Lipella Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/lipo-stock-quote/">LIPO</a>) shares are falling over 17% <a href="https://investorplace.com/2024/07/why-is-lipella-pharmaceuticals-lipo-stock-up-149-today/">after a rally yesterday</a>.</li>



<li>Cognition Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgtx-stock-quote/">CGTX</a>) stock is dropping more than 16% as it continues downward movement <a href="https://investorplace.com/2024/07/why-is-cognition-therapeutics-cgtx-stock-down-33-today/">on study results</a>.</li>



<li>NLS Pharmaceutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nlsp-stock-quote/">NLSP</a>) shares are sliding over 14% <a href="https://investorplace.com/2024/07/why-is-nls-pharmaceutics-nlsp-stock-up-48-today/">following a merger rally yesterday</a>.</li>



<li>Troops (NASDAQ:<a href="https://investorplace.com/stock-quotes/troo-stock-quote/">TROO</a>) stock is decreasing more than 13% today.</li>



<li>Loop Media (NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) shares close out our pre-market stock movers down over 12% after <a href="https://www.stocktitan.net/news/LPTV/loop-media-inc-announces-new-partnership-and-nationwide-launch-of-u3mffuxudp5v.html">jumping yesterday on a new partnership</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-30th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

T2 Biosystems ( ($TTOO) ) just unveiled an update. T2 Biosystems, Inc. is on the brink of launching several innovative direct-from-blood diagnostic...

T2 Biosystems: Pioneering Rapid Diagnostic Tests Launch

The latest announcement is out from T2 Biosystems ( ($TTOO) ). T2 Biosystems has announced FDA clearance for its T2Candida Panel for use in pediatr...

T2 Biosystems Gains FDA Nod for Pediatric Sepsis Test

T2 Biosystems ( ($TTOO) ) just unveiled an announcement. T2 Biosystems has announced the successful defense of a crucial patent for its innovative ...

T2 Biosystems Reinforces Patent Victory in EU Market

T2 Biosystems reports 35% rise in Q3 revenue

T2 Biosystems, Inc. (TTOO) Business Update Conference Call Transcript

BIMI

CGTX

DTCK

EKSO

ENVB

HLIT

IMNN

ISPO

JTAI

LIPO

LPTV

LSCC

NLSP

PHAR

SERV

TROO

Press Releases

T2 Biosystems to Attend Upcoming Investor Conferences

T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

T2 Biosystems Provides Updates on its New Product Development Pipeline Progress

T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

Legal

T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union

T2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood Culture

T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

T2 Biosystems to Host Business Update Call on October 10, 2024

Canaccord Genuity

Alliance Global Partners

Comments

T2 Biosystems

Notizie

Ultime notizie per T2 Biosystems (NASDAQ:TTOO) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO